Price
$83.89-16.12%Social Signal Score
Analyst Ratings
13 analystsRevenue
$203.00M+10837.77%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Waleed H. Hassanein
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 898
- Beta
- 2.10
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.74
Financials
Revenue
$203.00M+10837.8%Net Income
$17.07MEBITDA
$42.21MFree Cash Flow
$27.60MEPS (diluted)
$0.46Shares Outstanding (diluted)
40.83M+778.9%Operating Expenses
$90.52MCash & Debt
$492.96MRevenue by Segment (annual)
$605.49MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $605.49M | $190.29M | $5.60 |
| 2024 | $441.54M | $35.46M | $1.07 |
| 2023 | $241.62M | $-25.03M | $-0.77 |
| 2022 | $93.46M | $-36.23M | $-1.23 |
| 2021 | $30.26M | $-44.22M | $-1.60 |
| 2020 | $25.64M | $-28.75M | $-1.16 |
| 2019 | $23.60M | $-33.55M | $-2.36 |
| 2018 | $13.02M | $-23.76M | $-1.23 |
| 2017 | $7.68M | $-20.82M | $-1.44 |
| 2016 | $6.21M | $-24.07M | $-1.66 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $8.23
- Implied price
- $180.95
- Return from $85.25
- 16.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $89.97 — today's price is already 5.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -2.0% | -1.0% | 2.4% | 5.5% | 8.2% | 10.7% |
| 3.0% | 4.0% | 7.7% | 10.9% | 13.7% | 16.3% |
| 8.0% | 9.1% | 12.9% | 16.2% | 19.3% | 22.0% |
| 13.0% | 14.1% | 18.1% | 21.6% | 24.8% | 27.6% |
| 18.0% | 19.2% | 23.3% | 27.0% | 30.3% | 33.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
43-13.33%Social Signal Score
Mentions (24)
- Newsdefenseworld.net·5d ago·Neutral
TransMedics Group (NASDAQ:TMDX) Stock Breaks Above Two Hundred Day Moving Average – Here’s Why TransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $91.80 and traded as high as $92.99. TransMedics Group shares last traded at $92.21, with a volume of 564,162 shares trading hands. Analyst Upgrades and Downgrades A number
View source ↗ - Newsseekingalpha.com·11d ago·Positive
…A Pivotal Year TransMedics Group is reiterated as a 'strong buy' due to compelling valuation and significant upside potential tied to multi-organ platform expansion. TMDX's 2027 catalysts include ENHANCE Heart, DENOVO Lung, CHOPS, OCS Kidney, and European expansion, all critical for achieving ambitious transplant volume targets. Q3 2026 saw record $203M revenue (+41% YoY), with management raising 2026 guidance to $764–$774M and operating margins expected at 12.5%–14%.
View source ↗ - Newszacks.com·12d ago·Positive
TransMedics (TMDX) Just Reclaimed the 200-Day Moving Average TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 200-day moving average, which suggests a long-term bullish trend.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
TransMedics: Growth Is Accelerating Again And 2027 Looks Promising TransMedics Group Inc. demonstrates accelerating revenue growth, improved service margins, and market share gains in the recent quarter. TransMedics raised full-year revenue guidance to $764-774 million, with organic growth of 24-26% and service revenue up 60% YoY. Key 2027 growth catalysts include European expansion, new heart and lung programs, and the early-stage kidney opportunity.
View source ↗ - Newsfool.com·13d ago·Positive
TransMedics: 3 Key Takeaways for Long-Term Investors TransMedics raised 2026 revenue guidance to $764 million to $774 million. Third-quarter revenue reached $203 million, up 41% year over year.
View source ↗ - Newszacks.com·13d ago·Positive
TransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy? TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 20-day moving average, which suggests a short-term bullish trend.
View source ↗ - Newszacks.com·13d ago·Positive
TransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
View source ↗ - Newsmarketbeat.com·16d ago·Positive
TransMedics Group Q3 Earnings Call Highlights TransMedics Group NASDAQ: TMDX raised its full-year revenue outlook after reporting record third-quarter revenue and transplant case volume, as gains in its liver and heart businesses helped offset a decline in U.S. deceased donor volume.
View source ↗ - Newsschaeffersresearch.com·16d ago·Neutral
Unusual Options Volume Report: 3 Stocks Moving After Earnings Three stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).
View source ↗ - Newszacks.com·17d ago·Neutral
TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Positive
TransMedics (TMDX) Q3 Earnings and Revenues Surpass Estimates TransMedics (TMDX) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.66 per share a year ago.
View source ↗ - Newsprnewswire.com·17d ago·Positive
… Company for Continued Growth with Several Near- and Mid-Term Catalysts ANDOVER, Mass., Nov. 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2026.
View source ↗ - Newszacks.com·18d ago·Neutral
Reasons to Retain TransMedics Stock in Your Portfolio for Now TMDX's OCS technology, robust pipeline and global expansion support growth prospects, but margin pressures and rising investments remain key concerns.
View source ↗ - Newszacks.com·18d ago·Neutral
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings Looking beyond Wall Street's top-and-bottom-line estimate forecasts for TransMedics (TMDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
View source ↗ - Newsbusinesswire.com·21d ago·Negative
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $TMDX--TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsprnewswire.com·23d ago·Neutral
…sMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 28, 2026, the Company granted non-qualified stock options to purchase an aggregate of 71,815 shares of its common stock and an aggregate of 47,924 restricted st…
View source ↗ - Newsprnewswire.com·24d ago·Neutral
TransMedics to Present at Upcoming Investor Conferences ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in three upcoming investor conferences.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
TransMedics selects Gogo Galileo HDX for nationwide organ transport fleet Reliable, high-performance connectivity will support time-critical transport and monitoring of donor organs for transplants aboard 22 Embraer Phenom 300E aircraft Reliable, high-performance connectivity will support time-critical transport and monitoring of donor organs for transplants aboard 22 Embraer Phenom 300E aircraft
View source ↗ - Newsprnewswire.com·31d ago·Neutral
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026 ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026.
View source ↗ - Newszacks.com·80d ago·Positive
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure? TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
View source ↗ - Newszacks.com·80d ago·Neutral
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report? TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsprnewswire.com·83d ago·Neutral
TransMedics to Present at Upcoming September Investor Conferences ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
View source ↗ - Newsmarketbeat.com·96d ago·Neutral
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion TransMedics Group NASDAQ: TMDX outlined its growth strategy at Canaccord Genuity's 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $0.41 per share
Typical surprise +71.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.51 vs $0.30beat
- Tue, Aug 4$0.44 vs $0.50miss
- Tue, May 5$0.30 vs $0.62miss
- Tue, Feb 24$0.57 vs $0.41beat
- Wed, Oct 29$0.66 vs $0.37beat
- Wed, Jul 30$0.92 vs $0.48beat
Estimates and results for TMDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TMDX officers and directors.
- Bought
- $3.1m
- Sold
- $8.0m
5 trades
23 trades
- Tobin James Rsold
- Tobin James Rsold
- Weill Davidbought
- Gunderson Thomas J.sold
- Lovell Stephaniesold
- Weill Davidsold
- Hernandez Gerardosold
- Hernandez Gerardosold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TMDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
